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Chronic inﬂammation is a hallmark of neurodegenerative disease and cytotoxic levels of nitric oxide (NO)
and pro-inﬂammatory cytokines can initiate neuronal death pathways. A range of cellular assays were
used to assess the anti-inﬂammatory and neuroprotective action of resveratrol using murine microglial
(C8eB4), macrophage (RAW264.7) and neuronal-like (Neuro2a) cell lines. We examined the release of
NO by Griess assay and used a Bioplex array to measure a panel of pro- and anti-inﬂammatory cytokines
and chemokines, in response to the inﬂammatory stimuli lipopolysaccharide (LPS) and interferon-g (IFN-
g).
Resveratrol was a potent inhibitor of NO and cytokine release in activated macrophages and microglia.
The activity of resveratrol increased marginally in potency with longer pre-incubation times in cell
culture that was not due to cytotoxicity. Using an NO donor we show that resveratrol can protect
Neuro2a cells from cytotoxic concentrations of NO. The protective effect of resveratrol from pro-
inﬂammatory signalling in RAW264.7 cells was conﬁrmed in co-culture experiments leading to
increased survival of Neuro2a cells. Together our data are indicative of the potential neuroprotective
effect of resveratrol during nitrosative stress and neuroinﬂammation.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic inﬂammation is known to be an important etiological
condition for various chronic diseases, including atherosclerosis,, cytokine suppressing anti-
lating factor; GM-CSF, gran-
terferon; IL, interleukin; JNK,
PK, mitogen activated protein
a; NF-kB, nuclear factor-kB;
atory drugs; SNAP, S-Nitroso-
cal Research Institute, School
longong, Northﬁelds Avenue,
Ltd. This is an open access article udiabetes, and arthritis. Furthermore, increasing evidence suggests
that innate immune activation is a major component of age-related
neurodegenerative diseases, such as Alzheimer's and Parkinson's
disease (for recent reviews see (Heneka et al., 2014; Norden et al.,
2015)).
Inﬂammatory cells, includingmacrophages andmicroglia, play a
major role in the body's response to immunogenic challenges, by
re-establishing tissue homeostasis, producing large amounts of
superoxide, nitric oxide (NO) and pro-inﬂammatory cytokines that
aggravate and propagate inﬂammation and disrupt the normal
function of cells. For example, the pro-inﬂammatory cytokine,
tumour necrosis factor-a (TNF-a), binds to two tumour necrosis
factor receptors TNFR1 and TNFR2 and, depending on the adaptor
protein, activates various signalling pathways including nuclear
factor-kB (NF-kB), and the mitogen activated protein kinases
(MAPK), p38 and c-Jun N-terminal kinase (JNK), which can lead tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
N. Steiner et al. / Neurochemistry International 95 (2016) 46e54 47proliferation, cell migration, apoptosis and necrosis (McCoy and
Tansey, 2008).
NO is a signalling molecule with diverse cellular roles; it is
released by macrophages, neurons and endothelial cells and can
be either protective or toxic to cells depending on the cellular
context (Ooi et al., 2013a; Gamper and Ooi, 2015). The toxicity of
NO is attributed to its ability to bind to proteins that contain
heme, iron, copper or organic side groups, such as thiols,
resulting in protein disruption and alterations in cellular activ-
ities. As a result of reactivity with a wide range of cellular
components, high levels of NO are toxic to neurons, while low
levels can be neuroprotective (Balez and Ooi, 2015). Similarly
there is evidence that activation of microglia could have a pro-
tective role in neurodegenerative diseases (Luo and Chen, 2012;
Kan et al., 2015). Therefore promoting anti-inﬂammatory cyto-
kines or limiting pro-inﬂammatory cytokine and NO production
by activated macrophages/microglia should be beneﬁcial for
prevention of systemic and local inﬂammation and would be
potentially neuroprotective.
To date, pharmacotherapy of inﬂammatory conditions is
based on the use of non-steroidal anti-inﬂammatory drugs
(NSAIDs). However, NSAIDs can cause serious gastrointestinal
toxicity such as gastric bleeding and the formation of stomach
ulcers. Some NSAIDs, particularly cyclooxygenase-2 (COX-2) in-
hibitors, have been linked to increased blood pressure, greatly
increased risk of congestive heart failure, thrombosis and
myocardial infarction (Mitchell and Warner, 2006). NSAIDs are
inhibitors of cyclooxygenase and speciﬁcally suppress the pro-
duction of prostaglandins (Vane et al., 1998). Thus the identiﬁ-
cation of anti-inﬂammatory treatments with fewer adverse
effects and drugs with broader anti-inﬂammatory properties is
an important task. One such therapeutic approach involves
suppressing the production of interleukin-1 (IL-1), TNF-a and
other NF-kB regulated cytokines at the level of transcription,
translation and/or secretion. The activities associated with
certain of pyridinyl imidazoles involve a class of compounds
referred to as cytokine suppressing anti-inﬂammatory drugs
(CSAIDs) (Karunaweera et al., 2015).
The stilbene resveratrol (3,40,5-trihydroxy-trans-stilbene) is a
polyphenol CSAID found in grapes, red wine, mulberries knot-
weed, peanuts and other plants. Resveratrol dampens inﬂam-
mation in arthritis (Elmali et al., 2007) and immune
responsiveness in autoimmune disease (Singh et al., 2010).
Resveratrol can also penetrate the blood brain barrier in vivo
(Baur et al., 2006), however the effect of resveratrol on a broad
range of pro- and anti-inﬂammatory factors has not previously
been investigated.
In the present study, we ﬁrst examined the expression of various
pro- and anti-inﬂammatory cytokines, chemokines and NO by
murine microglia (C8eB4) and macrophages (RAW264.7) in
response to the inﬂammatory stimuli lipopolysaccharide (LPS) and
interferon-g (IFN-g). We then determined the effects of resveratrol
on cytokines and chemokines in activated C8eB4 microglia and
RAW264.7 macrophages and investigated the effect of the pre-
incubation time in cell culture on the calculated potency. Resver-
atrol potently inhibited the release of NO and a number of cytokines
from activated macrophages and microglia and was able to protect
neuronal-like Neuro2a cells from cytotoxic concentrations of NO.
Conditioned media from activated RAW264.7 cells reduced the
viability of Neuro2a cells, an effect that was prevented by pre-
treatment of the activated RAW264.7 cells with resveratrol.
Together our results highlight the anti-inﬂammatory effects of
resveratrol and its potential as a neuroprotective agent against
neuroinﬂammation.2. Materials and methods
2.1. Materials
The 23-multiplex cytokine assay was from Bio-rad (Gladesville,
Australia). All cell culture materials were from Invitrogen (Mul-
grave, Australia). Cell culture plasticware including Primaria plates
was from Greiner Bio-One (Frickenhausen, Germany), Protease in-
hibitor cocktail, naphthyethylene-diamine, sulfanilamide, Corning®
Costar® Spin-X® spin ﬁlter, LPS (from Salmonella enteric serotype
thyphimurium), resazurin and S-Nitroso-N-acetyl-DL-penicilla-
mine (SNAP) were from SigmaeAldrich (Castle Hill, Australia).
Interferon-g was from Pepro Tech (Rocky Hill, USA). TrypLE Ex-
press™ was purchased from Life Technologies (Mulgrave,
Australia). Cell lines were obtained from the ATCC.
2.2. Cell maintenance
RAW264.7, C8eB4 and Neuro2a cells weremaintained in DMEM
containing 25mM glucose, supplementedwith 200 U/ml penicillin,
200 mg/ml streptomycin, 200 mM glutamine (GlutaMax, Gibco) and
10% fetal bovine serum. Cells were grown in 75 cm2 tissue culture
ﬂasks and incubated at 37 C in 5% CO2. RAW264.7 and Neuro2a
cells were detached from the ﬂask with a rubber policeman and
split 1:10 every 5 days. C8eB4 cells were split 1:2 every 2 weeks
and partial medium changes were performed twice a week.
2.3. Resveratrol treatment of LPS and IFN-g activated C8eB4 and
RAW264.7 cells and SNAP-treated Neuro2a cells
Cells were washed twice with PBS and harvested with TrypLE
Express. Cells were then plated in a 96-well plate at a density of
60,000 cells/well and incubated for 24 h before treatment. Cells
were pre-treated with resveratrol for 1 h before adding the acti-
vationmix containing 12.5 mg/ml LPS and 5 Units IFN-g for 24 h. The
total volume of medium in each well was 100 ml and to obtain
enough supernatant for further analysis, the supernatant from 3
wells was combined. The supernatant was spin ﬁltered (0.2 mm
Corning spin ﬁlter) and 0.4 ml protease inhibitor cocktail containing
Aprotinin, Bestatin, E64, Leupeptin and Pepstatin A (Sigma) was
added. Fifty microlitres of supernatant was immediately used for
measuring NO and the remainder was stored at 80 C for later
analysis by cytokine array. Neuro2a cells were pre-treated with
resveratrol for 1 h before treatment with the NO donor, SNAP, at
concentrations ranging from 0.1 to 1000 mM or the vehicle control
(DMSO). Cells were harvested for cell viability assays and the su-
pernatant collected for Griess assay to measure nitrite
concentration.
2.4. Neuro2a incubation with conditioned media from activated
RAW264.7 cells
As in Section 2.3 RAW264.7 cells were plated at a density of
60,000 cells/well and incubated for 24 h before treatment.
RAW264.7 cells were activatedwith 12.5 mg/ml LPS and 5 Units IFN-
g for 24 h. Cells were pre-treatedwith 100 mM resveratrol or vehicle
control (DMSO) for 1 h prior to inﬂammatory activation. Neuro2a
cells were seeded at a density of 60,000 cells per well in a 96-well
plate, and incubated for 24 h. Media from RAW264.7 cells were
added to Neuro2a cells. As a further control, Neuro2a cells were also
pre-treated with 100 mM resveratrol or vehicle control (DMSO) for
1 h prior to application of RAW264.7 conditioned media. After 24 h
of incubation with conditioned media from RAW264.7 cells, the
Neuro2a cells were assessed by cell viability and Griess assay. The
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cells.
2.5. Resazurin-based assay for determination of cell viability
Cell viability was assessed in terms of themetabolic capability of
cells to convert the non-ﬂuorescent redox indicator, resazurin, into
its highly ﬂuorescent product, resoruﬁn. DMEM (100 ml) containing
0.125 mg/l resazurin was added to each well of a 96-well plate and
incubated for 90min a 37 C. Fluorescencewasmeasured at 560 nm
excitation/590 nm emission using a BMG Labtech POLARstar
Omega ﬂuorescent plate reader (BMG LABTECH, Ortenberg,
Germany).
2.6. Nitrite determination by Griess assay
The nitrite concentration in the culture medium was measured
as an indicator of NO production using the Griess reaction. Super-
natant from each well (50 ml) was transferred to a fresh 96 well
plate and 25 ml of 1% sulfanilamide plus 25 ml of 0.1%
napthyethylene-diamine in 5% HCl were added. When combined,
these compounds (known as Griess reagent), form a violet colour in
the presence of nitrite. After 10 min incubation at room tempera-
ture, the absorbance of each well was measured at 540 nm using a
Bio-Rad Model 680 Microplate reader (Bio-Rad, Gladesville,
Australia). Nitrite concentration was calculated with reference to a
standard curve of sodium nitrite generated by known concentra-
tions, ranging from 0 to 100 mM.
2.7. Determination of cytokine levels using a Bioplex cytokine assay
A panel of 23 cytokines was measured, using a Bioplex Pro™
mouse cytokine 23-plex kit (Bio-Rad, Gladesville, Australia), ac-
cording to the manufacturer's protocol.
2.8. Data analysis
The standard error of the mean (SEM) and all other values were
calculated from at least three independent experiments. Signiﬁcant
differences were assessed by one-way ANOVA with Tukey's mul-
tiple comparisons test. IC50 values for resveratrol were calculated
using the sigmoidal doseeresponse function.
3. Results
3.1. LPS and IFN-g activation increases NO and cytokine/chemokine
release in murine RAW264.7 and C8eB4 cells
For the determination of the potency of a CSAID, cell lines with a
broad range of cytokine and chemokine response are needed. These
cell lines should react upon stimulation with pro-inﬂammatory
stimuli, such as LPS and IFN-g, with up-regulation of inducible ni-
tric oxide synthase (with resulting NO production and release), as
well as increased expression and release of pro-inﬂammatory cy-
tokines such as TNF-a, interleukin-1a (IL-1a), IL-1b, IL-6, IL-12, as
well as chemokines such as granulocyte colony-stimulating factor
(G-CSF).
When both cell lines were activated with a combination of LPS
and IFN-g, a signiﬁcant increase in NO production (determined as
nitrite) was observed. The activated macrophage cell line
RAW264.7 released approximately four times more NO compared
to C8eB4 cells (Table 1). In addition, 17 different inﬂammatory
markers were determined using the Bioplex Pro™mouse cytokine
23-plex immunoassay (6 markers were below detection threshold;
Table 1).In both cell lines, activation with LPS and IFN-g for 24 h led to a
signiﬁcant up-regulation of the pro-inﬂammatory cytokines IL-1a,
IL-6, TNF-a, IL-12(p40) and the chemokines G-CSF and CeC motif
chemokine 5 (CCL5, also known as RANTES). Activation also up-
regulated the anti-inﬂammatory cytokines IL-10 and IL-13 in
RAW264.7 macrophage cells but not in C8eB4 microglia. The che-
mokines monocyte chemotactic protein 1 (MCP-1), macrophage
inﬂammatory protein-1a (Mip-1a), Mip-1b, were also only up-
regulated in RAW 264.7, but not in C8eB4 microglia. In general,
the C8eB4 cells showed a more limited cytokine/chemokine
release repertoire than the RAW264.7 cells under the same acti-
vation conditions (Table 1).
3.2. Resveratrol prevents NO and cytokine release in RAW264.7 and
C8eB4 cells but has a limited effect on chemokine release
To answer the question as to whether resveratrol possesses
broad anti-inﬂammatory actions, cells were pre-incubated with
resveratrol at concentrations up to 100 mM for 1 h prior to activa-
tion by LPS and IFN-g in RAW264.7 and C8eB4 cells, after which the
release of NO, cytokines and chemokines was measured. Only those
pro-inﬂammatory markers that had shown an up-regulation of
>1.5 fold in the previous experiment were analysed. An anti-
inﬂammatory effect of resveratrol (deﬁned as an IC50
value < 100 mM) could be demonstrated in both cell lines. Resver-
atrol down-regulated the pro-inﬂammatory cytokines IL-1a, IL-1b,
IL-6 and TNF-a in both RAW264.7 and C8eB4 cells. However, it
also down-regulated the anti-inﬂammatory cytokine IL-10 in
RAW264.7 cells only (Table 2). Resveratrol effects on chemokines
were more limited, leading to down-regulation of only MCP-1 and
RANTES in RAW264.7 (Table 3).
3.3. Increasing pre-incubation time marginally increases potency of
resveratrol
Since the effects of inﬂammatory activationweremore potent in
the RAW264.7 cells and since resveratrol was more effective in
limiting inﬂammatory activation of RAW264.7 cells, we continued
our experiments using this cell line only. One of the most funda-
mental questions to judge the clinical efﬁcacy of a compound is
whether the concentration of the compound in the human body is
in the same order of magnitude as its IC50 value. However, it might
be possible that some cell culture experiments are also conducted
under suboptimal conditions, and effective concentrations are
higher than needed. For example, a very short pre-incubation time
might make it impossible or difﬁcult for the compound to reach an
intracellular target, whereas long pre-incubation times might lead
to substantial degradation of the compound.
Wewanted to determine whether our experimental setup of 1 h
pre-incubation time affected potency, resulting in limited diffusion
of resveratrol into the cell. We hypothesized that the calculated
potencymight increasewhen the incubation timewas extended. To
answer this question, RAW264.7 cells were pre-incubated with
resveratrol for 1, 3, 6, 9 and 24 h before activationwith LPS and IFN-
g. NO was measured after 24 h to assess the potency of resveratrol.
In these experiments the calculated IC50 decreased from
44.7 ± 7.1 mMafter 1 h pre-incubation to 26.7± 3.5 mMafter 6 h pre-
incubation, increasing after 24 h pre-incubation (Fig. 1). To exclude
the possibility that the decrease in the release of the pro-
inﬂammatory markers were caused by cell death, cytotoxicity of
resveratrol was measured in RAW264.7 and C8eB4 cells. At pre-
incubation times of 1 h, and concentrations below 100 mM,
resveratrol did not show cytotoxicity in RAW264.7 cells. Only at a
concentration of 110 mM did resveratrol cause a decrease in cell
viability by 13% in C8eB4 cells (data not shown). The LC50 values
Table 1
Comparison of cytokine & chemokine responses to activation with LPS and IFN-g in RAW264.7 and C8-B4 cells. Data are shown as mean concentration (pg/ml) ± SEM from 3
independent experiments and fold change. Underline denotes anti-inﬂammatory cytokines. Signiﬁcant difference between unactivated and activated cells denoted as
* ¼ p < 0.05, ** ¼ p < 0.01, *** ¼ p < 0.001, ns ¼ not signiﬁcant.
Inﬂammatory response marker Concentration in RAW 264.7
macrophages (pg/ml)
Upregulation (fold) Concentration in C8-B4 microglia
(pg/ml)
Upregulation (fold)
Unactivated Activated Unactivated Activated
Nitric oxide (mM) 1.0 ± 0.4 60 ± 4 60*** 1.3 ± 0.3 16.4 ± 0.8 13***
IL-1 a 46.0 ± 1.4 331 ± 21 7*** 17 ± 2 158 ± 37 9.3**
IL-1 b 2585 ± 149 3203 ± 81 1.2* 1502 ± 48 1459 ± 277 ns
IL-6 12 ± 3 10522 ± 822 877*** 21 ± 5 572 ± 117 27**
IL-9 1195 ± 133 2132 ± 224 1.8** 140 ± 3 154 ± 11 ns
IL-12(p40) 44 ± 6 88 ± 6 2.0** 129 ± 11 1051 ± 234 8.1**
IL-12(p70) 413 ± 15 1252 ± 22 3.0*** 314 ± 29 286 ± 74 ns
TNF-a 237 ± 5 142870 ± 8619 603*** 304 ± 60 9395 ± 2085 31**
G-CSF 25 ± 1 113944 ± 12150 4558*** 155 ± 64 7070 ± 2191 46**
GM-CSF 417 ± 9 716 ± 22 1.7*** 302 ± 25 375 ± 46 ns
IL-10 91 ± 3 10358 ± 765 114*** 122 ± 7 117 ± 23 ns
IL-13 749 ± 19 2105 ± 50 3.0*** 876 ± 42 915 ± 196 ns
Eotaxin 1430 ± 63 4234 ± 414 3.0*** 1928 ± 134 2399 ± 260 ns
KC 23 ± 2 55 ± 2 2.4*** 20 ± 1 47 ± 7 2.3**
MCP-1 534 ± 69 45626 ± 5286 85*** 23226 ± 1794 26115 ± 8948 ns
Mip-1a 66979 ± 6675 177204 ± 22988 2.6* 4559 ± 582 5526 ± 3711 ns
Mip-1b 13336 ± 1089 538430 ± 3531 40*** 12933 ± 622 9336 ± 2573 ns
RANTES 150 ± 3 35472 ± 3226 236*** 92 ± 41 752 ± 226 8*
Table 2
Effect of resveratrol on cytokine levels in RAW264.7 and C8eB4 cells. Data shown
aremean IC50 of resveratrol (mM) ± SEM from 3 independent experiments, n.d.¼ not
determined. Underline denotes anti-inﬂammatory cytokines.
Cytokine Cells IC50 (mM)
IL-1a RAW264.7 95 ± 11
C8eB4 68 ± 15
IL-6 RAW264.7 53 ± 14
C8eB4 99 ± 21
IL-9 RAW264.7 >136
C8eB4 >110
IL-12(p40) RAW264.7 >136
C8eB4 >110
IL-12(p70) RAW264.7 >136
C8eB4 n.d.
TNF-a RAW264.7 62 ± 8
C8eB4 42 ± 6
G-CSF RAW264.7 >136
C8eB4 50 ± 6
GM-CSF RAW264.7 >136
C8eB4 60 ± 11
IL-10 RAW264.7 37 ± 2
C8eB4 >110
Fig. 1. The effect of resveratrol pre-incubation time on inhibition of NO release.
Dose response curves for resveratrol induced down-regulation of nitrite in RAW264.7
cells with different pre-incubation times prior to inﬂammatory activation with LPS and
IFN-g. Data shown are mean ± SEM, n ¼ 3.
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remained the same in all pre-treatment ranges but increased only
after 24 h pre-treatment (Table 4). The increase in NO production atTable 3
Effect of resveratrol on chemokine levels in RAW264.7 and C8eB4 cells. Data shown
aremean IC50 of resveratrol (mM) ± SEM from 3 independent experiments, n.d.¼ not
determined.
Chemokine Cells IC50 (mM)
Eotaxin RAW264.7 >136
C8eB4 n.d.
KC RAW264.7 >136
C8eB4 >110
MCP-1 RAW264.7 77 ± 7
C8eB4 >110
Mip-1a RAW264.7 >136
C8eB4 >110
Mip-1b RAW264.7 >136
C8eB4 >110
RANTES RAW264.7 63 ± 7
C8eB4 >11024 h pre-treatment was therefore likely due to an increase in cell
number following 24 h pre-incubation. Our data suggest that the
calculated potency of resveratrol increases 1.6 fold with increasing
pre-incubation times and this is not due to an alteration in cell
viability.
3.4. Resveratrol protects Neuro2a cells from cytotoxic levels of NO
The neuroprotective and neurodegenerative capacity of in-
ﬂammatory cells are central to understanding pathways pertinent
to neuronal survival. Identifying molecules that promote neuronal
survival is central to preventing neurodegeneration. The simplest
way to study these effects is to remove contributing factors and
study one component of the system. To determine whether
resveratrol could be neuroprotective against cytotoxic concentra-
tions of NO, Neuro2a cells were treated with 1 mM resveratrol for
6 h prior to incubationwith the NO donor, SNAP. This concentration
was chosen based on our previous experiments in Neuro2a cells
and because resveratrol reaches nanomolar to micromolar con-
centrations in the plasma and brain (Nguyen et al., 2013; Walker
et al., 2014). SNAP incubation at concentrations of 0.1 and 1 mM
did not increase nitrite levels above vehicle control, as measured by
Griess assay (no signiﬁcant difference from control). SNAP at con-
centrations of 10, 100 and 1000 mM increased nitrite levels in
Neuro2a media by 4, 15 and 100 fold, respectively (Fig. 2), with no
signiﬁcant difference in nitrite levels measured in the media from
Table 4
IC50 and LC50 values for resveratrol at different pre-incubation times in RAW264.7.
Data shown are mean ± SEM, n ¼ 3.
Pre-incubation time (h) IC50 for NO inhibition (mM) LC50 (mM)
1 44.7 ± 7.1 143.7 ± 18.8
3 39.7 ± 5.7 153.8 ± 17.0
6 26.7 ± 3.5 152.6 ± 20.5
9 28.0 ± 3.6 141.9 ± 29.8
24 53.6 ± 17.4 249.4 ± 165.4
Fig. 3. The effects of the NO donor SNAP on cell viability following pre-treatment
with resveratrol. Neuro2a cells were incubated with 1 mM resveratrol or vehicle
control for 6 h prior to treatment with vehicle or 0.1, 1, 10, 100 or 1000 mM of the NO
donor SNAP and incubated for 24 h. Cell viability was measured by resazurin assay.
Data shown are mean ± SEM, n ¼ 3. Signiﬁcant interactions were determined by two-
way ANOVA; # denotes p < 0.05 SNAP treatment compared to vehicle control; * de-
notes p < 0.05 resveratrol treatment compared to vehicle control.
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ranging from 0.1 to 100 mM SNAP had no effect on Neuro2a cell
viability, while 1000 mM SNAP was neurotoxic, reducing cell
viability by 22 ± 5% (p < 0.05, n ¼ 3; Fig. 3) compared to vehicle
control. Even at the lowest concentration of resveratrol tested in
macrophages and microglia (1 mM) resveratrol was able to protect
Neuro2a against cytotoxic concentrations of NO and nitrosative
stress (Fig. 3). Resveratrol increased cell viability in the presence of
10, 100 and 1000 mM SNAP by 2.7, 2.9 and 2.1 fold, respectively, and
was thus able to prevent the cytotoxic effects of 1000 mM SNAP.
Since resveratrol was able to protect cells against cytotoxic
concentrations of NO, we further investigated its potential as a
neuroprotective agent. The neuroprotective effect of resveratrol
was tested in a macrophage-neuron co-culture experiment using
the transfer of conditioned media, as described previously (Münch
et al., 2003). Media were incubated with RAW264.7 cells for 24 h
and then incubated with Neuro2a cells. RAW264.7 cells were pre-
treated with 100 mM resveratrol or vehicle control (DMSO) for 1 h
prior to inﬂammatory activation and activated with 12.5 mg/ml LPS
and 5 Units IFN-g for 24 h, as in the previous experiments. Media
from RAW264.7 cells were added to Neuro2a cells and after 24 h
incubation cell viability and Griess assays were performed for the
RAW264.7 and Neuro2a cells. As expected, inﬂammatory activation
of RAW264.7 cells led to a dramatic up-regulation of nitrite in the
media of RAW264.7 cells (Fig. 4A). Nitrite remained at similar levels
24 h after transfer of the media to the Neuro2a cells (Fig. 4B). Pre-
incubation of the RAW264.7 cells with 100 mM resveratrol pre-
vented increases in nitrite that remained present in the media that
was transferred to the Neuro2a cells and incubated for 24 h (Fig. 4A,
B). Resveratrol treatment alone on RAW264.7 (without inﬂamma-
tory activation) had no effect on the viability of Neuro2a cells
(Fig. 5A). Conversely, inﬂammatory activation of RAW264.7 led to a
reduction in Neuro2a viability that was reduced by pre-incubation
of RAW264.7 with resveratrol. As further controls, media contain-
ing the inﬂammatory mixes, with or without resveratrol were
added direct to the Neuro2a cells in the absence of incubation with
RAW264.7 cells (Fig. 5B). Application of this media had no signiﬁ-
cant effect on viability of Neuro2a cells in any of the conditions,
showing that the reduction in Neuro2a viability was caused byFig. 2. Quantitation of nitrite following incubation with the NO donor SNAP.
Neuro2a cells were incubated with 1 mM resveratrol or vehicle control for 6 h prior to
treatment with vehicle or 0.1, 1, 10, 100 or 1000 mM of the NO donor SNAP and incu-
bated for 24 h. Nitrite levels in the cell media were measured by Griess assay. Data
shown are mean ± SEM, n ¼ 3.molecules secreted by activated RAW264.7 cells. In addition, Neu-
ro2a cells were pre-treated with 100 mM resveratrol or vehicle
control (DMSO) for 1 h prior to application of RAW264.7 condi-
tionedmedia (Figs. 4 and 5). This treatment had no further effect on
nitrite levels or Neuro2a viability, suggesting that the neuro-
protective effects observed were speciﬁcally due to the anti-
inﬂammatory effects of resveratrol on RAW264.7 cells. Together
these data highlight the potential neuroprotective role for the ac-
tion of resveratrol via its anti-inﬂammatory actions, in addition to
its ability to protect against cytotoxic levels of NO.4. Discussion
4.1. RAW264.7 macrophages exhibited a more reactive phenotype
than C8eB4 microglia, releasing higher levels of nitric oxide and
pro-inﬂammatory cytokines
During brain inﬂammation, the microglia proliferate and
migrate to the inﬂammatory lesion (Kettenmann et al., 2011). Blood
derived macrophages may also enter the brain via the blood brain
barrier. (Guillemin and Brew, 2004). In the central nervous system
two different macrophage populations have a role to play in sup-
porting neurons, and these are often described as CNS-resident
microglia and CNS-inﬁltrating peripheral macrophages. In neuro-
degenerative diseases, such as Alzheimer's disease, CNS-inﬁltrating
peripheral macrophages may contribute to neurodegeneration,
however activated microglia may also protect neurons by removing
toxic aggregates and cellular debris (Kraft and Harry, 2011). Func-
tional differences in CNS-resident microglia and acutely inﬁltrating
inﬂammatory macrophages have been identiﬁed (Carson et al.,
2007). Thus an understanding of cell-type speciﬁc effects and the
differences in commonly used cellular models of macrophages and
microglia is important to identify the roles these cells play in
neuroprotection/neurodegeneration (Simard et al., 2006).
Activated microglia behave similarly to macrophages by
inducing cytotoxicity in a variety of cells through the release of NO
(Brantley et al., 2010). It is likely that some microglia develop from
a pool of blood monocytes and colonize the brain early in devel-
opment (Lawson et al., 1990, 1992). Evidence suggests that LPS and
IFN-g-activated microglia isolated from the adult brain are more
similar to macrophages inﬁltrating the CNS than naive microglia of
the brain (Schmid et al., 2009). Therefore it is important to
consider the responses of each of these cell types to activation and
the effects of any neuroprotective agents in preventing these re-
sponses. To address this we have carried out a comprehensive
study on the anti-inﬂammatory effects of resveratrol, a polyphenol
Fig. 4. Inﬂammatory activation of RAW264.7 cells caused increases in nitrite measured by Griess assay. (A) Griess assay on RAW264.7 cells treated with LPS and IFN-g for
24 h ± 1 h pre-incubation with resveratrol (100 mM) in RAW264.7 cells. Samples were untreated, treated with vehicle (veh) or resveratrol (resv) ± inﬂammatory activation (inﬂam;
LPS and IFN-g). (B) The media was transferred from RAW264.7 cells to Neuro2A cells and incubated with Neuro2A cells for 24 h prior to Griess assay. To conﬁrm the effects were
driven by resveratrol on the RAW264.7 cells rather than on Neuro2A cells, Neuro2A cells were also pre-treated with vehicle or resveratrol prior to application of the RAW264.7
media (Veh (pre-treat) þ inﬂam; Resv (pretreat) þ Inﬂam). Data shown are mean ± SEM, n ¼ 4.
Fig. 5. Conditioned media from inﬂammatory activated RAW264.7 cells reduced viability of Neuro2A cells, which could be prevented with resveratrol treatment of
RAW264.7 cells. (A) Cell viability of RAW264.7 cells 24 h following treatment with inﬂammatory activators (inﬂam; LPS and IFN-g) ± pre-incubation for 1 h with vehicle (veh) or
resveratrol (resv) as in Fig. 4. To conﬁrm the effects were driven by resveratrol on the RAW264.7 cells rather than on Neuro2A cells, Neuro2A cells were also pre-treated with vehicle
or resveratrol prior to application of the RAW264.7 media (Veh (pre-treat) þ inﬂam; Resv (pretreat) þ Inﬂam). (B) Cell viability of Neuro2A cells was measured following transfer of
the same media mixes as in (A) but these were added directly to the Neuro2a cells in the absence of incubation with RAW264.7 cells. Data shown are mean ± SEM, n¼4.
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roprotective actions (reviewed in (Jayasena et al., 2013)). To study
the effects of resveratrol we compared macrophage and microglial
cell lines during activation by LPS and IFN-g. Both cell lines
expressed a panel of pro-inﬂammatory cytokines following acti-
vation, though C8eB4 microglial cells were more limited in their
repertoire. RAW264.7 macrophages released higher levels of 15
out of 17 cytokines tested and four times as much NO (measured
as nitrite) compared to C8eB4 microglial cells. Therefore
RAW264.7 macrophages show a more reactive phenotype than C8-
B4 cells following activation with the same concentrations of LPS
and IFN-g.
4.2. Resveratrol exhibits anti-inﬂammatory properties
Resveratrol reduced 7 out of 9 pro-inﬂammatory cytokines from
C8eB4 cells and 5 out of 9 pro-inﬂammatory cytokines from
RAW264.7 cells. It also signiﬁcantly reduced nitrite levels in both
lines, but had a more limited effect on chemokine release, reducingonly MCP-1 and RANTES in macrophages. Additionally, resveratrol
treatment did also reduce the anti-inﬂammatory cytokine IL-10.
However our experiments also showed that resveratrol protects
against pro-inﬂammatory or cytotoxic molecules released into the
media by activatedmacrophages. Importantly the concentrations of
resveratrol that had an identiﬁable anti-inﬂammatory effect are
consistent with concentrations that can be found in the plasma (mM
levels) (Walker et al., 2014). In addition it is likely that resveratrol
metabolites, including resveratrol-3-sulfate also possess anti-
inﬂammatory activities that could provide further anti-
inﬂammatory activity (Walker et al., 2014).
Consistent with our ﬁndings, resveratrol reduced the levels of
IL-6, NO, and TNF-a in RAW264.7 cells (Yang et al., 2014). In this
study, the expression levels of high mobility group protein B1 and
toll-like receptor 4 were reduced following resveratrol treatment,
hinting at potential mechanisms involved in these anti-
inﬂammatory effects. Our study builds on these ﬁndings
providing a comprehensive view of the down-regulation of cyto-
kines by resveratrol. A previous study identiﬁed that resveratrol
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mation, potentially through up-regulation of AMP-activated pro-
tein kinase (AMPK) and sirtuin-1 (Dong et al., 2014). Our data
together with that of others is therefore generating a picture of the
broad anti-inﬂammatory actions of resveratrol. Such broad and
potent anti-inﬂammatory activities have led to proposals of
resveratrol treatment for diverse conditions, including cancer (Jang
et al., 1997), pain (Gentilli et al., 2001), neurodegenerative disease
(Virgili and Contestabile, 2000), obesity (Baur et al., 2006), diabetes
(Su et al., 2006), rheumatoid arthritis (Elmali et al., 2007) and
depression (Xu et al., 2010). However, there are also examples in
which resveratrol dietary supplementation worsened clinical
severity, for example in viral and autoimmune mouse models of
multiple sclerosis (Sato et al., 2013), suggesting that resveratrol
would make a poor option for therapeutic treatment of demyelin-
ating diseases. In addition, our data suggest that there is a narrow
therapeutic window for resveratrol with higher levels contributing
to cytotoxicity. The design of the study focuses on the protective
effects of resveratrol in reducing pro-inﬂammatory cytokines and
the release of soluble cytotoxic factors but it must also be noted that
there are many putative beneﬁcial biological roles of activation of
these cells. For example, activation of microglia allows the removal
of toxic aggregates and cellular debris and the effects of resveratrol
in vivo must be tempered with the possibility that local immune
suppression contributes to neurodegeneration (Kan et al., 2015).
Similarly, as a counter to the reductions in pro-inﬂammatory cy-
tokines by resveratrol treatment, it must be noted that resveratrol
also inhibited the release of the anti-inﬂammatory cytokine, IL-10,
and had a limited effect on chemokine release. A recent study using
hippocampal astrocytes identiﬁed a role for resveratrol in down-
regulating TNF-a, IL-1b, IL-6 and IL-10 in astrocytes following LPS
activation (Bellaver et al., 2015). The mechanisms identiﬁed were
similar to those in neurons and involved NF-kB, p38 and MAPK
signalling (Bellaver et al., 2015). Other mechanisms proposed for
the protective effects of resveratrol in primary astrocytes are
reviewed in (Quincozes-Santos and Gottfried, 2011). For example,
changes in glutamate handling (Vieira de Almeida et al., 2007) and
protection via the activation of nuclear factor erythroid 2-related
factor 2 (Erlank et al., 2011), a transcription factor that protects
astrocytes against glutathione reduction and oxidative stress
(Steele et al., 2013a, 2013b) have been implicated. Future in vivo
studies and co-culture experiments will help to delineate the spe-
ciﬁc roles of individual cytokines and chemokines in distinct cell
types in mediating neurodegenerative and neuroprotective
mechanisms.
4.3. Effects of resveratrol in vivo and its potential as a
neuroprotective agent
An in-depth study of the levels of inﬂammatory markers in
humans following resveratrol ingestion has not yet been carried
out. However, consistent with our ﬁndings of a large down-
regulation of pro-inﬂammatory molecules, a small study using an
extract of Polygonum Cuspidatum (containing 40 mg resveratrol)
taken daily for 6 weeks did lead to the reduction of plasma con-
centrations of TNF-a and IL-6 (Ghanim et al., 2010). In a recent
study in a mouse model of familial Alzheimer's disease, long-term
resveratrol treatment reduced amyloid and prevented memory
loss, potentially via activation of sirtuin-1 and AMPK signalling
pathways (Porquet et al., 2014). Surprisingly this occurred even
following an increase in IL-1b and TNF-a. Potent anti-inﬂammatory
activity for resveratrol has now been identiﬁed in a number of
disease models in mice, including reduced lung inﬂammation
through increasing superoxide dismutase, glutathione peroxidase,
and catalase activity by enhancing nuclear translocation of NF-kBand heme oxygenase-1 activity (Liu et al., 2014). Multiple mecha-
nisms for the neuroprotective activity of resveratrol have been
identiﬁed (reviewed in (Renaud and Martinoli, 2014)). Suggested
mechanisms for resveratrol in protecting neurons against Alz-
heimer's disease include by preventing oxidative stress and toxic
amyloid aggregation (Ladiwala et al., 2010; Shariatizi et al., 2015)
and this could occur by augmentation in the expression and activity
of anti-oxidant enzymes, such as catalase and superoxide dismut-
ase (Sadi and Konat, 2015). Other ﬁndings have highlighted a
mechanism of action for resveratrol in activating sirtuin-1 to inhibit
p53 transcription and enhance neuroprotection (Feng et al., 2015)
or via MAPKs, NF-kB and nicotinamide adenine dinucleotide
phosphate-oxidase (NADPH oxidase) signalling pathways (Zhang
et al., 2010).
We have previously shown that resveratrol has pro-energetic
effects in Neuro2a cells with the ability to increase ATP and GTP
levels in the cells (Nguyen et al., 2013). In line with this, resver-
atrol increased cell viability, an effect that was most evident in
cells treated with high levels of the NO donor but not in the
absence of NO (Figs. 2, 4 and 5). NO is a potent activator of AMPK
and in turn AMPK protects cells against the damaging effects of
NO; in pancreatic b cells this mechanism involves activation of
inositol-requiring enzyme 1 (Meares et al., 2011). During disrup-
tion of energy homeostasis AMPK is activated by an increased
AMP/ATP ratio (Sanders et al., 2007). In pancreatic b cells AMPK
activation by NO improved metabolic function of b-cells to prevent
cell death following NO treatment (Sanders et al., 2007). Resver-
atrol did not increase the energy charge potential (a measure of
energy status of the cell) of Neuro2a cells in conditions of sufﬁ-
cient nutrition but only during starvation conditions (Nguyen
et al., 2013). Our current results suggest that resveratrol is also
protective under conditions of nitrosative stress in Neuro2a cells.
Our data do not support a role for resveratrol in direct scavenging
of nitric oxide (Figs. 2, 4 and 5) but rather suggest it promotes a
cytoprotective pathway. Thus it is possible that resveratrol pro-
motes cell survival of Neuro2a cells against NO-mediated cell
death via the activation of AMPK, in addition to its anti-
inﬂammatory effects.
An important issue in considering resveratrol as a potential
neuroprotective agent is whether it can exert functional effects in
the brain following peripheral administration or ingestion. In line
with this consideration, brain inﬂammation caused by streptozo-
tocin injections induced cognitive impairment in rats, yet memory
performance was enhanced following peripheral resveratrol
administration (Sharma and Gupta, 2002). In mice, resveratrol
administration upregulated sirtuin-1 to protect neurons against
neurodegeneration in models of Alzheimer's disease and motor
neurone disease (Kim et al., 2007). These ﬁndings have now been
conﬁrmed in adult primates, in which dietary resveratrol treat-
ment (200 mg/kg/day) for 18 months increased working memory
and cognitive performance (Dal-Pan et al., 2011). Importantly,
these studies have recently been extended to humans and a pic-
ture of the neuroprotective effects of resveratrol in aging adults is
emerging. Following 26 weeks of resveratrol intake (200 mg/day)
older adults showed signiﬁcant increases in hippocampal func-
tional connectivity and memory performance, demonstrating an
increased retention of words (Witte et al., 2014). We have studied
the effects of nitric oxide and inﬂammation on Neuro2a cell
viability. Technical developments in generating the many distinct
cell types of the brain using induced pluripotent stem cells will
provide a more accurate model of the human nervous system
in vitro (Ooi et al., 2013b). Future studies will capitalise on these
advancements to identify the contribution of distinct cell types
and molecular mechanisms involved in neuroprotection and
neurodegeneration.
N. Steiner et al. / Neurochemistry International 95 (2016) 46e54 535. Conclusions
The ﬁndings from our study suggest that resveratrol has broad
anti-inﬂammatory effects and is capable of down-regulating pro-
inﬂammatory responses in cellular models of both CNS-resident
microglia and CNS-inﬁltrating peripheral macrophages. Our ﬁnd-
ings provide further evidence of the neuroprotective potential of
resveratrol during neuroinﬂammation.
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